To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Columbia (ECOS COL)
Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Columbia
Sponsor: Merck KGaA, Darmstadt, Germany
A observational or N/A phase clinical study on Growth Disorders, this trial is completed. The trial is conducted by Merck KGaA, Darmstadt, Germany and has accumulated 9 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jan 2019 — Jan 2021 [monthly]
Completed
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2018 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Jan 2018 [monthly]
Completed NA
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
- Merck S.A. Columbia
For direct contact, visit the study record on ClinicalTrials.gov .